Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$110.94 USD

110.94
7,458,602

+1.05 (0.96%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $110.95 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Medtronic (MDT) Progresses in CGM With New Approval, Alliance

The FDA approval for Medtronic's (MDT) Simplera CGM sets the stage for further regulatory submissions of the updated InPen smart insulin pen app.

Urmimala Biswas headshot

Abbott Up 7.7% Post Q2 Earnings: Should You Buy ABT Stock?

Abbott's (ABT) strong growth projection for 2024 is an indication that the stock will be able to sustain the positive momentum through the rest of the year.

OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down

Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.

Envista (NVST) Q2 Earnings & Revenues Miss, Margins Fall

Envista's (NVST) Spark division sales witness a slowdown in the second quarter due to the deferment of a larger portion of case revenues.

Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up

Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.

National Vision (EYE) Tops Q2 Earnings, Lowers '24 Outlook

National Vision (EYE) delivers an earnings beat in the second quarter of 2024 and announces new transformative actions for long-term growth.

Myriad Genetics (MYGN) Q2 Earnings Surpass, '24 Outlook Raised

Myriad Genetics (MYGN) delivers a strong performance across its portfolio in the second quarter of 2024 and increases its long-term revenue growth rate target.

Charles River (CRL) Q2 Earnings Beat Estimates, 2024 View Down

Charles River's (CRL) Manufacturing business segments report organic revenue growth, partially offset by lower revenues in the DSA and RMS segments.

Zimmer Biomet (ZBH) Beats on Q2 Earnings, Cuts Revenue View

Zimmer Biomet's (ZBH) strategic expansion of international business contributes to the top line in the second quarter.

STERIS (STE) Q1 Earnings Beat Estimates, Operating Margin Falls

STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.

Globus Medical (GMED) Q2 Earnings Top Estimates, '24 View Up

Globus Medical (GMED) delivers massive sales and earnings growth in the second quarter of 2024. However, margins contract.

CVS Health (CVS) Beats Q2 Earnings, Narrows '24 EPS Outlook

CVS Health (CVS) delivers a year-over-year improvement in revenues, driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments.

Is Trending Stock Abbott Laboratories (ABT) a Buy Now?

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Bruker (BRKR) Q2 Earnings Meet Mark, '24 Revenue Outlook Raised

Bruker (BRKR) delivers robust revenue growth in the second quarter despite soft general market conditions.

IDEXX (IDXX) Q2 Earnings Miss Estimates, 2024 View Down

IDEXX's (IDXX) Q2 earnings miss estimates but revenues meet the same.

Henry Schein (HSIC) Q2 Earnings Surpass, 2024 Guidance Slashed

Henry Schein's (HSIC) second-quarter results reflect an improvement in sales trends in distribution businesses.

Debanjana Dey headshot

Hims & Hers (HIMS) Gains 45.8% in Three Months: What's Next?

Hims & Hers (HIMS) is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.

Tandem Diabetes (TNDM) Q2 Earnings Beat, '24 View Raised

Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered

Bio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.

Abbott (ABT) Just Overtook the 200-Day Moving Average

Should investors be excited or worried when a stock crosses above the 200-day simple moving average?

Omnicell (OMCL) Q2 Earnings Top Estimates, Margins Down

Omnicell's (OMCL) Q2 results outpace expectations despite a challenging customer environment.

Teleflex (TFX) Tops Q2 Earnings Estimates, Raises 2024 Outlook

Teleflex's (TFX) diversified portfolio and global footprint have driven durable growth in the second quarter of 2024.

ResMed's (RMD) Q4 Earnings Surpass Estimates, Margins Expand

ResMed (RMD) delivers solid performance across all regions and business segments in the fourth quarter of fiscal 2024.

Mark Vickery headshot

Labcorp (LH) Q2 Earnings Surpass Estimates (revised)

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.